{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T07:29:15Z","timestamp":1794468555590,"version":"4.9.1"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T00:00:00Z","timestamp":1676332800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T00:00:00Z","timestamp":1676332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["Juan de la Cierva (FJC2018-036012-I)"],"award-info":[{"award-number":["Juan de la Cierva (FJC2018-036012-I)"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["Proyectos de Generaci\u00f3n de Conocimiento grants PID2021-122473OA-I00, PID2021-123462OB-I00 and PID2019-106625RB-I00"],"award-info":[{"award-number":["Proyectos de Generaci\u00f3n de Conocimiento grants PID2021-122473OA-I00, PID2021-123462OB-I00 and PID2019-106625RB-I00"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["Sara Borrell (CD22\/00125)"],"award-info":[{"award-number":["Sara Borrell (CD22\/00125)"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["Acci\u00f3n Estrat\u00e9gica en Salud grants PI17\/01474, PI19\/00335, PI22\/01403 and PI22\/00258"],"award-info":[{"award-number":["Acci\u00f3n Estrat\u00e9gica en Salud grants PI17\/01474, PI19\/00335, PI22\/01403 and PI22\/00258"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015496","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red sobre Enfermedades Neurodegenerativas","doi-asserted-by":"publisher","award":["Support grants CB06\/05\/2004 and CB18\/05\/00010"],"award-info":[{"award-number":["Support grants CB06\/05\/2004 and CB18\/05\/00010"]}],"id":[{"id":"10.13039\/501100015496","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013278","name":"EU Joint Programme \u2013 Neurodegenerative Disease Research","doi-asserted-by":"publisher","award":["PREADAPT project, grant N\u00ba AC19\/00097"],"award-info":[{"award-number":["PREADAPT project, grant N\u00ba AC19\/00097"]}],"id":[{"id":"10.13039\/100013278","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Agency for Innovation and Entrepreneurship","award":["HARPONE project, grant N\u00ba PR067\/21"],"award-info":[{"award-number":["HARPONE project, grant N\u00ba PR067\/21"]}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["ADAPTED project, grant N\u00ba 115975"],"award-info":[{"award-number":["ADAPTED project, grant N\u00ba 115975"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["DESCARTES"],"award-info":[{"award-number":["DESCARTES"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010434","name":"\u201cla Caixa\u201d Foundation","doi-asserted-by":"publisher","award":["GR@ACE project"],"award-info":[{"award-number":["GR@ACE project"]}],"id":[{"id":"10.13039\/100010434","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016387","name":"Grifols","doi-asserted-by":"publisher","award":["GR@ACE project"],"award-info":[{"award-number":["GR@ACE project"]}],"id":[{"id":"10.13039\/501100016387","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In the clinical course of Alzheimer\u2019s disease (AD) development, the dementia phase is commonly preceded by a prodromal AD phase, which is mainly characterized by reaching the highest levels of A\u03b2 and p-tau-mediated neuronal injury and a mild cognitive impairment (MCI) clinical status. Because of that, most AD cases are diagnosed when neuronal damage is already established and irreversible. Therefore, a differential diagnosis of MCI causes in these prodromal stages is one of the greatest challenges for clinicians. Blood biomarkers are emerging as desirable tools for pre-screening purposes, but the current results are still being analyzed and much more data is needed to be implemented in clinical practice. Because of that, plasma extracellular vesicles (pEVs) are gaining popularity as a new source of biomarkers for the early stages of AD development. To identify an exosome proteomics signature linked to prodromal AD, we performed a cross-sectional study in a cohort of early-onset MCI (EOMCI) patients in which 184 biomarkers were measured in pEVs, cerebrospinal fluid (CSF), and plasma samples using multiplex PEA technology of Olink<jats:sup>\u00a9<\/jats:sup>proteomics. The obtained results showed that proteins measured in pEVs from EOMCI patients with established amyloidosis correlated with CSF p-tau<jats:sup>181<\/jats:sup>levels, brain ventricle volume changes, brain hyperintensities, and MMSE scores. In addition, the correlations of pEVs proteins with different parameters distinguished between EOMCI A\u03b2(\u2009+) and A\u03b2(-) patients, whereas the CSF or plasma proteome did not. In conclusion, our findings suggest that pEVs may be able to provide information regarding the initial amyloidotic changes of AD. Circulating exosomes may acquire a pathological protein signature of AD before raw plasma, becoming potential biomarkers for identifying subjects at the earliest stages of AD development.<\/jats:p><jats:p><jats:bold>Graphical Abstract<\/jats:bold><\/jats:p>","DOI":"10.1186\/s12951-023-01793-7","type":"journal-article","created":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T14:05:11Z","timestamp":1676383511000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Plasma extracellular vesicles reveal early molecular differences in amyloid positive patients with early-onset mild cognitive impairment"],"prefix":"10.1186","volume":"21","author":[{"given":"Amanda","family":"Cano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Esteban-de-Antonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireia","family":"Bernuz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Puerta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Garc\u00eda-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itziar","family":"de Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Oliv\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"P\u00e9rez-Cord\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Montrreal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ra\u00fal","family":"N\u00fa\u00f1ez-Llaves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d3scar","family":"Sotolongo-Grau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Alarc\u00f3n-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergi","family":"Valero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Alegret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela V.","family":"Martino-Adami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miren","family":"Ettcheto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Camins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assumpta","family":"Vivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Gomez-Chiari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel \u00c1ngel","family":"Tejero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adelina","family":"Orellana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Llu\u00eds","family":"T\u00e1rraga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Marqui\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merc\u00e8","family":"Mart\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Isabel","family":"Pividori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merc\u00e8","family":"Boada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agust\u00edn","family":"Ru\u00edz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,14]]},"reference":[{"key":"1793_CR1","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1474-4422(18)30403-4","volume":"18","author":"E Nichols","year":"2019","unstructured":"Nichols E, Szoeke CEI, Vollset SE, Abbasi N, Abd-Allah F, Abdela J, et al. Global, regional, and national burden of Alzheimer \u2019 s disease and other dementias, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18:88\u2013106.","journal-title":"Lancet Neurol"},{"issue":"3","key":"1793_CR2","first-page":"1","volume":"17","author":"Alzheimer\u2019s Association","year":"2021","unstructured":"Alzheimer\u2019s Association. Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 2021;17(3):1\u2013103.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"1793_CR3","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein S, Holtzman DM, et al. Toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535\u201362.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"1793_CR4","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/acn3.166","volume":"2","author":"J Cummings","year":"2015","unstructured":"Cummings J, Isaacson R, Schmitt F, Velting D. A practical algorithm for managing Alzheimer\u2019 s disease: what, when, and why\u202f? Ann Clin Transl Neurol. 2015;2(3):307\u201323.","journal-title":"Ann Clin Transl Neurol"},{"issue":"3","key":"1793_CR5","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):280\u201392.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"1793_CR6","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/alz.12063","volume":"16","author":"KJ Joling","year":"2020","unstructured":"Joling KJ, Janssen O, Francke AL, Verheij RA, Lissenberg-Witte BI, Pieter-Jelle V, et al. Time from diagnosis to institutionalization and death in people with dementia. Alzheimers Dement. 2020;16(4):662\u201371.","journal-title":"Alzheimers Dement"},{"key":"1793_CR7","unstructured":"Alzheimer\u2019s Association. More than normal aging: understanding mild cognitive impairment. 2022.\u00a0https:\/\/www.alz.org\/media\/Documents\/alzheimers-facts-and-figures-special-report.pdf"},{"key":"1793_CR8","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jneumeth.2018.10.025","volume":"319","author":"H Zetterberg","year":"2019","unstructured":"Zetterberg H. Blood-based biomarkers for Alzheimer\u2019 s disease \u2014 An update. J Neurosci Methods. 2019;319:2\u20136.","journal-title":"J Neurosci Methods"},{"issue":"21","key":"1793_CR9","first-page":"00361","volume":"S1474\u20134422","author":"CE Teunissen","year":"2021","unstructured":"Teunissen CE, Verberk IMW, Thijssen EH, Vermunt L, Hansson O, Zetterberg H, et al. Blood-based biomarkers for Alzheimer\u2019s disease: towards clinical implementation. Lancet Neurol. 2021;S1474\u20134422(21):00361\u20136.","journal-title":"Lancet Neurol"},{"key":"1793_CR10","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.mcn.2018.12.001","volume":"97","author":"M Sch\u00f6ll","year":"2019","unstructured":"Sch\u00f6ll M, Maass A, Mattsson N, Ashton NJ, Blennow K, Zetterberg H, et al. Biomarkers for tau pathology. Mol Cell Neurosci. 2019;97:18\u201333.","journal-title":"Mol Cell Neurosci"},{"key":"1793_CR11","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3389\/fimmu.2015.00203","volume":"6","author":"J de Toro","year":"2015","unstructured":"de Toro J, Herschlik L, Mongini C, Waldner C. Emerging roles of exosomes in normal and pathological conditions: new insights for diagnosis and therapeutic applications. Front Immunol. 2015;6:203.","journal-title":"Front Immunol"},{"key":"1793_CR12","doi-asserted-by":"crossref","first-page":"eaau6977","DOI":"10.1126\/science.aau6977","volume":"367","author":"R Kalluri","year":"2020","unstructured":"Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367:eaau6977.","journal-title":"Science"},{"issue":"3","key":"1793_CR13","doi-asserted-by":"crossref","first-page":"721","DOI":"10.7150\/ijbs.79063","volume":"19","author":"A Cano","year":"2023","unstructured":"Cano A, Ettcheto M, Bernuz M, Puerta R, Esteban de Antonio E, Souto EB, et al. Extracellular vesicles, the emerging mirrors of brain physiopathology. Int J Biol Sci. 2023;19(3):721\u201343.","journal-title":"Int J Biol Sci"},{"issue":"9","key":"1793_CR14","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.4155\/tde.11.83","volume":"2","author":"MJ Wood","year":"2011","unstructured":"Wood MJ, O\u2019Loughlin AJ, Lakhal S. Exosomes and the blood\u2013brain barrier: implications for neurological diseases. Ther Deliv. 2011;2(9):1095\u20139.","journal-title":"Ther Deliv"},{"key":"1793_CR15","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2021.101321","volume":"68","author":"T Zhang","year":"2021","unstructured":"Zhang T, Ma S, Lv J, Wang X. The emerging role of exosomes in Alzheimer\u2019 s disease. Ageing Res Rev. 2021;68: 101321.","journal-title":"Ageing Res Rev"},{"issue":"1","key":"1793_CR16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00401-018-1868-1","volume":"136","author":"M Sardar","year":"2018","unstructured":"Sardar M, Anna S, Schultz A, Civitelli L, Hildesj\u00f6 C, Larsson M, et al. Alzheimer\u2019 s disease pathology propagation by exosomes containing toxic amyloid - beta oligomers. Acta Neuropathol. 2018;136(1):41\u201356.","journal-title":"Acta Neuropathol"},{"key":"1793_CR17","first-page":"12","volume":"9","author":"T Zheng","year":"2017","unstructured":"Zheng T, Pu J, Chen Y, Mao Y, Guo Z, Pan H. Plasma exosomes spread and cluster around \u03b2 -amyloid plaques in an animal model of Alzheimer\u2019 s disease. Front Aging Neurosci. 2017;9:12.","journal-title":"Front Aging Neurosci"},{"issue":"6","key":"1793_CR18","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jalz.2014.06.008","volume":"11","author":"MS Fiandaca","year":"2015","unstructured":"Fiandaca MS, Kapogiannis D, Mapstone M, Boxer A, Eitan E, Schwartz JB, et al. Identification of preclinical Alzheimer\u2019s disease by a profile of pathogenic proteins in neurally derived blood exosomes: a case-control study. Alzheimers Dement. 2015;11(6):600-607.e1.","journal-title":"Alzheimers Dement"},{"issue":"2","key":"1793_CR19","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1096\/fj.14-262048","volume":"29","author":"D Kapogiannis","year":"2015","unstructured":"Kapogiannis D, Boxer A, Schwartz JB, Abner EL, Biragyn A, Masharani U, et al. Dysfunctionally phosphorylated type 1 insulin receptor substrate in neural-derived blood exosomes of preclinical Alzheimer\u2019s disease. FASEB J. 2015;29(2):589\u201396.","journal-title":"FASEB J"},{"issue":"4","key":"1793_CR20","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/hbm.23494","volume":"38","author":"RJ Mullins","year":"2017","unstructured":"Mullins RJ, Mustapic M, Goetzl EJ, Kapogiannis D. Exosomal biomarkers of brain insulin resistance associated with regional atrophy in Alzheimer\u2019s disease. Hum Brain Mapp. 2017;38(4):1933\u201340.","journal-title":"Hum Brain Mapp"},{"issue":"1","key":"1793_CR21","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1212\/WNL.0000000000001702","volume":"85","author":"EJ Goetzl","year":"2015","unstructured":"Goetzl EJ, Boxer A, Schwartz JB, Abner EL, Petersen RC, Miller BL, et al. Altered lysosomal proteins in neural-derived plasma exosomes in preclinical Alzheimer disease. Neurology. 2015;85(1):40\u20137.","journal-title":"Neurology"},{"issue":"2","key":"1793_CR22","doi-asserted-by":"crossref","first-page":"4141","DOI":"10.1096\/fj.201600816R","volume":"30","author":"EJ Goetzl","year":"2016","unstructured":"Goetzl EJ, Kapogiannis D, Schwartz JB, Lobach IV, Goetzl L, Abner EL, et al. Decreased synaptic proteins in neuronal exosomes of frontotemporal dementia and Alzheimer\u2019s disease. FASEB J. 2016;30(2):4141\u20138.","journal-title":"FASEB J"},{"key":"1793_CR23","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.dadm.2018.11.002","volume":"11","author":"CN Winston","year":"2019","unstructured":"Winston CN, Goetzl EJ, Schwartz JB, Elahi FM, Rissman RA. Complement protein levels in plasma astrocyte-derived exosomes are abnormal in conversion from mild cognitive impairment to Alzheimer\u2019s disease dementia. Alzheimers Dement (Amst). 2019;11:61\u20136.","journal-title":"Alzheimers Dement (Amst)."},{"issue":"3","key":"1793_CR24","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.3233\/JAD-210254","volume":"83","author":"E Esteban de Antonio","year":"2021","unstructured":"Esteban de Antonio E, P\u00e9rez-Cord\u00f3n A, Gil S, Orellana A, Cano A, Alegret M, et al. BIOFACE: a prospective study of risk factors, cognition, and biomarkers in a cohort of individuals with early-onset mild cognitive impairment. study rationale and research protocols. J Alzheimers Dis. 2021;83(3):1233\u201349.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"1793_CR25","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13195-022-00988-8","volume":"14","author":"M Alegret","year":"2022","unstructured":"Alegret M, Sotolongo Grau O, De AEE, Cord\u00f3n AP, Orellana A, Espinosa A, et al. Automatized FACEmemory\u00ae scoring is related to Alzheimer\u2019 s disease phenotype and biomarkers in early - onset mild cognitive impairment\u202f: the BIOFACE cohort Open Access. Alzheimer\u2019s Res Ther. 2022;14(1):43.","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"1793_CR26","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jalz.2011.07.004","volume":"8","author":"H Vanderstichele","year":"2012","unstructured":"Vanderstichele H, Bibl M, Engelborghs S, Le Bastard N, Lewczuk P, Molinuevo JL, et al. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer\u2019s disease diagnosis: a consensus paper from the Alzheimer\u2019s biomarkers Standardization Initiative. Alzheimers Dement. 2012;8:65\u201373.","journal-title":"Alzheimers Dement"},{"issue":"6","key":"1793_CR27","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.jalz.2014.03.003","volume":"10","author":"JL Molinuevo","year":"2014","unstructured":"Molinuevo JL, Blennow K, Dubois B, Engelborghs S, Lewczuk P, Perret-Liaudet A, et al. The clinical use of cerebrospinal fluid biomarker testing for Alzheimer\u2019s disease diagnosis: a consensus paper from the Alzheimer\u2019s biomarkers standardization initiative. Alzheimers Dement. 2014;10(6):808\u201317.","journal-title":"Alzheimers Dement"},{"issue":"9","key":"1793_CR28","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13195-019-0550-8","volume":"11","author":"MJ Leit\u00e3o","year":"2019","unstructured":"Leit\u00e3o MJ, Silva-Sp\u00ednola A, Santana I, Olmedo V, Nadal A, Le BN, et al. Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer\u2019s disease. Alzheimers Res Ther. 2019;11(9):91.","journal-title":"Alzheimers Res Ther"},{"key":"1793_CR29","doi-asserted-by":"crossref","first-page":"6917","DOI":"10.2147\/IJN.S264498","volume":"15","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Bi J, Huang J, Tang Y, Du S, Li P. Exosome: a review of its classification, isolation techniques, storage, diagnostic and targeted therapy applications. Int J Nanomed. 2020;15:6917\u201334.","journal-title":"Int J Nanomed"},{"issue":"1","key":"1793_CR30","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s40478-019-0795-2","volume":"7","author":"CD Whelan","year":"2019","unstructured":"Whelan CD, Mattsson N, Nagle MW, Vijayaraghavan S, Hyde C, Janelidze S, et al. Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer\u2019 s disease. Acta Neuropathol Commun. 2019;7(1):169.","journal-title":"Acta Neuropathol Commun"},{"issue":"4","key":"1793_CR31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095192","volume":"9","author":"E Assarsson","year":"2014","unstructured":"Assarsson E, Lundberg M, Holmquist G, Bj\u00f6rkesten J, Thorsen SB, Ekman D, et al. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS ONE. 2014;9(4): e95192.","journal-title":"PLoS ONE"},{"key":"1793_CR32","unstructured":"Olink\u00a9Proteomics. Olink Target 96 Neurology. 2021.\u00a0https:\/\/olink.com\/products-services\/target\/neurology-panel\/"},{"key":"1793_CR33","unstructured":"Olink\u00a9Proteomics. Olink Target 96 Inflammation. 2021.\u00a0https:\/\/olink.com\/products-services\/target\/inflammation\/"},{"key":"1793_CR34","doi-asserted-by":"crossref","first-page":"6891","DOI":"10.3390\/ijms23136891","volume":"23","author":"A Orellana","year":"2022","unstructured":"Orellana A, Garc P, Valero S, Montrreal L, De RI, Hern I, et al. Establishing In-House Cutoffs of CSF Alzheimer\u2019 s Disease Biomarkers for the AT (N) stratification of the Alzheimer Center Barcelona Cohort. Int J Mol Sci. 2022;23:6891.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1793_CR35","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13195-020-00721-3","volume":"12","author":"A S\u00f6rensen","year":"2020","unstructured":"S\u00f6rensen A, Blazhenets G, Schiller F, Meyer PT, Frings L. Amyloid biomarkers as predictors of conversion from mild cognitive impairment to Alzheimer\u2019s dementia: a comparison of methods. Alzheimers Res Ther. 2020;12(1):155.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"1793_CR36","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/WAD.0b013e3182163b62","volume":"26","author":"LG Apostolova","year":"2012","unstructured":"Apostolova LG, Green AE, Babakchanian S, Hwang KS, Chou Y-Y, Toga AW, et al. Hippocampal atrophy and ventricular enlargement in normal aging, mild cognitive impairment (MCI), and Alzheimer Disease. Alzheimer Dis Assoc Disord. 2012;26(1):17\u201327.","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"3","key":"1793_CR37","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jalz.2016.02.002","volume":"12","author":"B Dubois","year":"2016","unstructured":"Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, et al. Preclinical Alzheimer\u2019s disease: definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016;12(3):292\u2013323.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"1793_CR38","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13024-019-0333-5","volume":"14","author":"MA DeTure","year":"2019","unstructured":"DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer\u2019s disease. Mol Neurodegener. 2019;14(1):32.","journal-title":"Mol Neurodegener"},{"issue":"10","key":"1793_CR39","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.1038\/s41380-021-01249-0","volume":"26","author":"H Hampel","year":"2021","unstructured":"Hampel H, Hardy J, Blennow K, Chen C, Perry G, Kim SH, et al. The amyloid-\u03b2 pathway in Alzheimer\u2019s disease. Mol Psychiatry. 2021;26(10):5481\u2013503.","journal-title":"Mol Psychiatry"},{"issue":"5","key":"1793_CR40","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/alz.12556","volume":"18","author":"JA Frontera","year":"2022","unstructured":"Frontera JA, Boutajangout A, Masurkar AV, Betensky RA, Ge Y, Vedvyas A, et al. Comparison of serum neurodegenerative biomarkers among hospitalized COVID-19 patients versus non-COVID subjects with normal cognition, mild cognitive impairment, or Alzheimer\u2019s dementia. Alzheimers Dement. 2022;18(5):899\u2013910.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"1793_CR41","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/ana.25542","volume":"86","author":"MP Pase","year":"2019","unstructured":"Pase MP, Himali JJ, Aparicio HJ, Romero JR, Satizabal CL, Maillard P, et al. Plasma total-tau as a biomarker of stroke risk in the community. Ann Neurol. 2019;86(3):463\u20137.","journal-title":"Ann Neurol"},{"issue":"(18 Suppl)","key":"1793_CR42","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1212\/WNL.98.18_supplement.1718","volume":"98","author":"H Aparicio","year":"2022","unstructured":"Aparicio H, Himali J, Himali D, Romero J, Lioutas V-A, Pase M, et al. Association of plasma nfl levels with risk of cardiovascular disease in the framingham heart study (S33.005). Neurology. 2022;98((18 Suppl)):1718.","journal-title":"Neurology"},{"key":"1793_CR43","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3389\/fnins.2017.00278","volume":"11","author":"M Mustapic","year":"2017","unstructured":"Mustapic M, Eitan E, Werner JK Jr, Berkowitz ST, Lazaropoulos MP, Tran J, et al. Plasma extracellular vesicles enriched for neuronal origin: a potential window into brain pathologic processes. Front Neurosci. 2017;11:278.","journal-title":"Front Neurosci"},{"key":"1793_CR44","doi-asserted-by":"crossref","first-page":"651","DOI":"10.3389\/fonc.2019.00651","volume":"9","author":"LM Garcia Cumba","year":"2019","unstructured":"Garcia Cumba LM, Peterson TE, Cepeda MA, Johnson AJ, Parney IF. Isolation and analysis of plasma-derived exosomes in patients with glioma. Front Oncol. 2019;9:651.","journal-title":"Front Oncol"},{"key":"1793_CR45","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.103192","volume":"63","author":"A Kumar","year":"2021","unstructured":"Kumar A, Kim S, Su Y, Sharma M, Kumar P, Singh S, et al. Brain cell-derived exosomes in plasma serve as neurodegeneration biomarkers in male cynomolgus monkeys self-administrating oxycodone. EBioMedicine. 2021;63: 103192.","journal-title":"EBioMedicine"},{"key":"1793_CR46","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41598-019-56542-4","volume":"10","author":"P Sharma","year":"2020","unstructured":"Sharma P, Diergaarde B, Ferrone S, Kirkwood JM, Whiteside TL. Melanoma cell-derived exosomes in plasma of melanoma patients suppress functions of immune effector cells. Sci Rep. 2020;10:92.","journal-title":"Sci Rep"},{"key":"1793_CR47","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jim.2014.06.007","volume":"411","author":"L Muller","year":"2014","unstructured":"Muller L, Hong C-S, Stolz DB, Watkins SC, Whiteside TL. Isolation of biologically-active exosomes from human plasma. J Immunol Methods. 2014;411:55\u201365.","journal-title":"J Immunol Methods"},{"issue":"10","key":"1793_CR48","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1212\/WNL.0b013e3181b23564","volume":"73","author":"A Okello","year":"2009","unstructured":"Okello A, Koivunen J, Edison P, Archer HA, Turkheimer FE, N\u00e5gren K, et al. Conversion of amyloid positive and negative MCI to AD over 3 years An 11C-PIB PET study. Neurology. 2009;73(10):754\u201360.","journal-title":"Neurology"},{"issue":"3","key":"1793_CR49","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/ana.25172","volume":"83","author":"EJ Goetzl","year":"2018","unstructured":"Goetzl EJ, Schwartz JB, Abner EL, Jicha GA, Kapogiannis D. High complement levels in astrocyte-derived exosomes of Alzheimer disease. Ann Neurol. 2018;83(3):544\u201352.","journal-title":"Ann Neurol"},{"issue":"2","key":"1793_CR50","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1096\/fj.201700731R","volume":"32","author":"EJ Goetzl","year":"2018","unstructured":"Goetzl EJ, Abner EL, Jicha GA, Kapogiannis D, Schwartz JB. Declining levels of functionally specialized synaptic proteins in plasma neuronal exosomes with progression of Alzheimer\u2019 s disease. FASEB J. 2018;32(2):888\u201393.","journal-title":"FASEB J"},{"key":"1793_CR51","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1093\/brain\/awaa376","volume":"144","author":"Z Ruan","year":"2021","unstructured":"Ruan Z, Pathak D, Kalavai SV, Yoshii-kitahara A, Bhatt N, Takamatsu-yukawa K, et al. Alzheimer\u2019 s disease brain-derived extracellular vesicles spread tau pathology in interneurons. Brain. 2021;144:288\u2013309.","journal-title":"Brain"},{"key":"1793_CR52","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s43587-021-00077-9","volume":"1","author":"G Brinkmalm","year":"2021","unstructured":"Brinkmalm G, Zetterberg H. The phosphorylation cascade hypothesis of Alzheimer\u2019s disease. Nature Aging. 2021;1:498\u20139.","journal-title":"Nature Aging"},{"issue":"2","key":"1793_CR53","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3233\/JAD-150172","volume":"46","author":"OV Forlenza","year":"2015","unstructured":"Forlenza OV, Miranda AS, Guimar I, Talib LL, Diniz BS, Gattaz WF, et al. Decreased neurotrophic support is associated with cognitive decline in non-demented subjects. J Alzheimers Dis. 2015;46(2):423\u20139.","journal-title":"J Alzheimers Dis"},{"issue":"8","key":"1793_CR54","doi-asserted-by":"crossref","first-page":"853","DOI":"10.2174\/156720511798192754","volume":"8","author":"G Straten","year":"2011","unstructured":"Straten G, Saur R, Laske C, Gasser T, Annas P, Basun H, et al. Influence of lithium treatment on GDNF serum and CSF concentrations in patients with early Alzheimer\u2019s disease. Curr Alzheimer Res. 2011;8(8):853\u20139.","journal-title":"Curr Alzheimer Res"},{"key":"1793_CR55","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/s43587-021-00071-1","volume":"1","author":"N Morshed","year":"2021","unstructured":"Morshed N, Lee MJ, Rodriguez FH, Lauffenburger DA, Mastroeni D, White FM. Quantitative phosphoproteomics uncovers dysregulated kinase networks in Alzheimer\u2019s disease. Nature Aging. 2021;1:550\u201365.","journal-title":"Nature Aging"},{"issue":"6","key":"1793_CR56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0234632","volume":"15","author":"DS Jonesco","year":"2020","unstructured":"Jonesco DS, Karsdal MA, Henriksen K. The CNS-specific proteoglycan, brevican, and its ADAMTS4-cleaved fragment show differential serological levels in Alzheimer\u2019s disease, other types of dementia and non-demented controls: a cross-sectional study. PLoS ONE. 2020;15(6): e0234632.","journal-title":"PLoS ONE"},{"issue":"2","key":"1793_CR57","doi-asserted-by":"crossref","first-page":"729","DOI":"10.3233\/JAD-201039","volume":"79","author":"K Minta","year":"2021","unstructured":"Minta K, Brinkmalm G, Portelius E, Johansson P, Svensson J, Kettunen P, et al. Brevican and neurocan peptides as potential cerebrospinal fluid biomarkers for differentiation between vascular dementia and Alzheimer\u2019s disease. J Alzheimers Dis. 2021;79(2):729\u201341.","journal-title":"J Alzheimers Dis"},{"issue":"S3","key":"1793_CR58","volume":"17","author":"M Tedeschi Dauar","year":"2021","unstructured":"Tedeschi Dauar M, Picard C, Rosa-Neto P, Villeneuve S, Poirier J. CNTN5 is associated with disease risk and pathology throughout the Alzheimer\u2019s disease continuum. Alzheimers Dement. 2021;17(S3): e052359.","journal-title":"Alzheimers Dement"},{"key":"1793_CR59","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3233\/JAD-141473","volume":"42","author":"M Mortamais","year":"2014","unstructured":"Mortamais M, Artero S, Ritchie K. White matter hyperintensities as early and independent predictors of Alzheimer\u2019s disease risk. J Alzheimers Dis. 2014;42:393\u2013400.","journal-title":"J Alzheimers Dis"},{"issue":"10","key":"1793_CR60","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.jalz.2019.06.4950","volume":"15","author":"S Moreno-Grau","year":"2019","unstructured":"Moreno-Grau S, de Rojas I, Hern\u00e1ndez I, Quintela I, Montrreal L, Alegret M, et al. Genome-wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer\u2019s disease and three causality networks: the GR@ACE project. Alzheimers Dement. 2019;15(10):1333\u201347.","journal-title":"Alzheimers Dement"},{"key":"1793_CR61","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3390\/biomedicines8070199","volume":"8","author":"JE Nielsen","year":"2020","unstructured":"Nielsen JE, Pedersen KS, Vesterg\u00e5rd K, Maltesen RG, Christiansen G, Lundbye-christensen S. Novel blood-derived extracellular vesicle-based proximity extension assay. Biomedicines. 2020;8:199.","journal-title":"Biomedicines"},{"issue":"12","key":"1793_CR62","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1038\/nm.2965","volume":"18","author":"J Vom Berg","year":"2012","unstructured":"Vom Berg J, Prokop S, Miller KR, Obst J, K\u00e4lin RE, Lopategui-Cabezas I, et al. Inhibition of IL-12\/IL-23 signaling reduces Alzheimer\u2019s disease-like pathology and cognitive decline. Nat Med. 2012;18(12):1812\u20139.","journal-title":"Nat Med"},{"key":"1793_CR63","doi-asserted-by":"crossref","first-page":"14057","DOI":"10.1038\/s41598-017-14020-9","volume":"7","author":"S Pedrini","year":"2017","unstructured":"Pedrini S, Gupta VB, Hone E, Doecke J, O\u2019Bryant S, James I, et al. A blood-based biomarker panel indicates IL-10 and IL-12\/23p40 are jointly associated as predictors of \u03b2-amyloid load in an AD cohort. Sci Rep. 2017;7:14057.","journal-title":"Sci Rep"},{"issue":"5","key":"1793_CR64","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0176760","volume":"12","author":"P Johansson","year":"2017","unstructured":"Johansson P, Almqvist EG, Wallin A, Johansson J-O, Andreasson U, Blennow K, et al. Reduced cerebrospinal fluid concentration of interleukin-12\/23 subunit p40 in patients with cognitive impairment. PLoS ONE. 2017;12(5): e0176760.","journal-title":"PLoS ONE"},{"key":"1793_CR65","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.3389\/fneur.2019.01065","volume":"10","author":"E Lin","year":"2019","unstructured":"Lin E, Kuo P-H, Liu Y-L, Yang AC, Tsai S-J. Association and interaction effects of interleukin-12 related genes and physical activity on cognitive aging in old adults in the Taiwanese population. Front Neurol. 2019;10:1065.","journal-title":"Front Neurol"},{"issue":"9","key":"1793_CR66","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1093\/brain\/awn146","volume":"131","author":"SM Nestor","year":"2008","unstructured":"Nestor SM, Rupsingh R, Borrie M, Smith M, Accomazzi V, Wells JL, et al. Ventricular enlargement as a possible measure of Alzheimer\u2019s disease progression validated using the Alzheimer\u2019s disease neuroimaging initiative database. Brain. 2008;131(9):2443\u201354.","journal-title":"Brain"},{"key":"1793_CR67","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jocn.2016.05.038","volume":"34","author":"T Ertekin","year":"2016","unstructured":"Ertekin T, Acer N, K\u00f6seo\u011flu E, Zarars\u0131z G, S\u00f6nmez A, G\u00fcm\u00fc\u015f K, et al. Total intracranial and lateral ventricle volumes measurement in Alzheimer\u2019s disease: a methodological study. J Clin Neurosci. 2016;34:133\u20139.","journal-title":"J Clin Neurosci"},{"issue":"22","key":"1793_CR68","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1212\/WNL.0000000000004688","volume":"89","author":"KA Walker","year":"2017","unstructured":"Walker KA, Hoogeveen RC, Folsom AR, Ballantyne CM, Knopman DS, Windham BG, et al. Midlife systemic inflammatory markers are associated with late-life brain volume. Neurology. 2017;89(22):2262\u201370.","journal-title":"Neurology"},{"issue":"3","key":"1793_CR69","first-page":"10783","volume":"2015","author":"I Arevalo-Rodriguez","year":"2015","unstructured":"Arevalo-Rodriguez I, Smailagic N, Roqu\u00e9iFiguls M, Ciapponi A, Sanchez-Perez E, Giannakou A, et al. Mini-Mental State Examination (MMSE) for the detection of Alzheimer\u2019s disease and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev. 2015;2015(3):10783.","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-023-01793-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-023-01793-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-023-01793-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T06:29:10Z","timestamp":1728887350000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-023-01793-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,14]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1793"],"URL":"https:\/\/doi.org\/10.1186\/s12951-023-01793-7","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,14]]},"assertion":[{"value":"19 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All protocols of the BIOFACE study have been approved by the Clinical Research Ethics Commission of the Hospital Clinic (Barcelona, Spain) in accordance with the current Spanish regulations in the field of biomedical research and the Declaration of Helsinki. Likewise, in accordance with Spain\u2019s Data Protection Law, all participants were informed about the study\u2019s goals and procedures by a neurologist before signing an informed consent form. Patients\u2019 privacy and data confidentiality were protected in accordance with applicable laws.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"We give our consent for the manuscript to be published in Journal of Nanobiotechnology.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors have no conflict of interest to state.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"54"}}